Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03001141
Other study ID # U1111-1190-5280
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date May 18, 2017
Est. completion date February 8, 2019

Study information

Verified date September 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a prospective, multicenter, non-randomized registry/observational study. The study will enroll up to 200 patients with successful St. Jude Medical (SJM) Cardiac Resynchronization Therapy (CRT) MP device implant from up to 10 centers.


Description:

Any patient receiving a market-approved SJM Quadra Assura MP (CRT-D) or newer model quadripolar device with MPP capability and who meets the inclusion criteria and none of the exclusion criteria is eligible for enrollment in the study.

Patients will be followed for 12 months after implant. Data will be collected after device implant (up to 30 days after successful implant), at 3, 6 and 12 months post-implant and during unscheduled visits.


Recruitment information / eligibility

Status Terminated
Enrollment 200
Est. completion date February 8, 2019
Est. primary completion date April 18, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient willing and able to sign Informed Consent Form

- Any patient receiving a market-approved SJM Quadra Assura MP (CRT-D) or newer model quadripolar device with MPP capability

Exclusion Criteria:

- Is likely to undergo a heart transplantation within 12 months

- Is less than 18 years old

- Is pregnant or is planning to get pregnant during the study

- Is currently taking part in a Clinical Trial with an active treatment group

- Life expectancy is under 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational
Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.

Locations

Country Name City State
Brazil Clinica Dom Rodrigo João Pessoa PB
Brazil BP São Paulo SP
Brazil Instituto de Arritmias Cardíacas São Paulo SP
Brazil SEMAP São Paulo SP

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac resynchronization therapy response rate measured by Clinical Composite Score Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Quality of Life changes, measured by MLWHF questionnaire Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Quality of Life changes, measured by EQ-5D questionnaire Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Change in left ventricular ejection fraction Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Change in left ventricular end systolic volume Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Programming strategy used (vector and intervals), obtained from the Device Session records Evaluated on regular medical visits and registered in the CRF 12 months
Secondary Heart failure hospitalization rate Evaluated on regular medical visits and registered in the CRF 12 months
Secondary All-cause mortality Evaluated on regular medical visits and registered in the CRF 12 months